Myelofibrosis: Symptoms, Causes and Treatment

The term myelofibrosis meaning can be explained as a bone marrow disorder in which scar tissue builds up and affects the production of healthy blood cells. Healthy blood cells perform different functions. Red blood cells carry oxygen to tissues, white blood cells help the body fight infections and platelets help stop bleeding by forming clots. The body may not produce enough red blood cells as the bone marrow becomes less effective which can lead to anaemia.

Scar tissue can interfere with the bone marrow's ability to produce enough red blood cells. A reduced red blood cell count can lead to anaemia which may cause tiredness, weakness and shortness of breath. Changes in white blood cell and platelet counts may also increase the risk of infections, bruising and bleeding.

When the bone marrow cannot produce enough blood cells, the spleen and sometimes the liver may begin producing them instead. This process is called extramedullary haematopoiesis. The spleen and liver may enlarge when they begin producing blood cells to compensate for reduced bone marrow function. An enlarged spleen can cause discomfort below the left ribs, abdominal fullness or a feeling of being full after eating only a small amount of food.

Myelofibrosis does not progress at the same rate in everyone. Some people remain stable for years with regular monitoring while others develop worsening symptoms or complications that require treatment. The appropriate care depends on the severity of the disease, the symptoms, the person's overall health and the risk of progression.

Myelofibrosis is associated with acquired genetic mutations in the bone marrow's blood-forming stem cells which affect how these cells grow and produce blood cells.

Mutations in the JAK2, CALR and MPL genes can disrupt signalling pathways that regulate blood cell production. Disrupted signalling may cause abnormal cell growth and contribute to bone marrow fibrosis. However, genetic testing may not identify mutations in any of the three genes in every person with myelofibrosis.

Most cases involve genetic changes acquired during a person's lifetime rather than a mutation inherited from a parent. The presence of a particular mutation can help doctors to assess the disease and guide treatment.

The bone marrow may become less effective at producing healthy blood cells as the abnormal cells multiply. Fibrous tissue accumulates, blood cell counts can change, and the spleen may begin producing blood cells to compensate for reduced bone marrow function.

Myelofibrosis is therefore not generally caused by one identifiable lifestyle choice or infection. Doctors diagnose myelofibrosis by assessing symptoms, blood test results, genetic mutations and the extent of scarring in the bone marrow.

Myelofibrosis symptoms vary depending on the extent of bone marrow damage, the bone marrow's ability to produce healthy blood cells and the progression of the disease. Some people have no noticeable symptoms in the early stages and myelofibrosis may first be suspected when a blood test reveals unusual blood cell counts. Common symptoms include the following:

• Fatigue and Weakness: A reduced number of red blood cells can cause anaemia, leaving a person feeling unusually tired, weak or short of breath during daily activities.
• Abdominal Pain or Fullness: An enlarged spleen can cause pain or discomfort in the upper-left abdomen just below the ribs. A person may also feel full after eating only a small amount of food.
• Easy Bruising and Bleeding: Abnormal or reduced platelet levels can affect blood clotting, leading to unexplained bruises, nosebleeds or other bleeding problems.
• Fever and Night Sweats: Some people experience unexplained fever or heavy night sweats that disturb sleep.
• Unintentional Weight Loss: Myelofibrosis may cause loss of appetite and unintentional weight loss.
• Bone Pain: Myelofibrosis can cause bone pain and tenderness due to changes in the bone marrow and inflammation of the tissues surrounding the bones.
• Frequent Infections: In some individuals, low or abnormal white blood cell levels can affect the body's ability to respond to infections.

These symptoms are not specific to myelofibrosis and can occur in several other medical conditions. Persistent fatigue, unexplained bruising, recurring fever or abdominal discomfort should therefore be assessed by a healthcare professional rather than treated as proof of myelofibrosis.

Diagnosis of myelofibrosis involves reviewing symptoms, checking for signs such as an enlarged spleen and investigating abnormal blood cell counts. No single symptom or routine blood test is sufficient to establish the diagnosis in every case. Doctors may use the following tests and assessments:

• Physical Examination: The doctor reviews symptoms and medical history and checks for an enlarged spleen or liver. Abdominal fullness or discomfort may provide additional clinical information.
• Complete Blood Count (CBC): A blood test measures red blood cells, white blood cells, haemoglobin and platelets. Abnormal levels may indicate anemia or other changes associated with a bone marrow disorder.
• Blood Smear Examination: A laboratory specialist examines the shape and appearance of blood cells under a microscope. The findings can reveal abnormal cell forms that may support further investigation.
• Bone Marrow Aspiration and Biopsy: A sample of bone marrow is collected, commonly from the pelvic bone. The sample helps specialists examine blood-forming cells and assess the extent of fibrosis and other abnormalities.
• Molecular and Genetic Testing: Tests may look for mutations in the JAK2, CALR and MPL genes. The results can help support classification and inform prognosis although the absence of these mutations does not automatically exclude the disease.
• Imaging Tests: Ultrasound, CT or MRI scans may be used to assess the size of the spleen and liver or investigate other findings.

Doctors diagnose myelofibrosis by assessing blood test results, bone marrow findings, genetic changes and clinical symptoms against established diagnostic criteria. A haematologist may also need to distinguish myelofibrosis from other myeloproliferative neoplasms and bone marrow conditions that can produce similar results.

After diagnosis, the medical team may use a prognostic scoring system to estimate the risk of disease progression. Such assessments can consider age, haemoglobin levels, white blood cell counts, circulating immature blood cells, symptoms and genetic or chromosomal findings. Doctors use the risk category to decide how often to monitor the disease and whether treatment should begin or be adjusted.

Myelofibrosis treatment aims to manage symptoms, address complications, maintain quality of life and, where possible, slow the effects of the disease. The treatment plan will depend on the type of myelofibrosis, severity of symptoms, risk category of the disease and several other factors.

People with low-risk myelofibrosis and no significant symptoms may not need treatment straight away. Regular check-ups and blood tests help doctors monitor the condition and identify any signs of progression. The medical team selects an approach based on the individual's needs when treatment becomes necessary.

Watchful Waiting: People who have no significant symptoms or complications may undergo regular medical examinations and blood tests without starting treatment immediately. Regular check-ups and blood tests help doctors detect worsening symptoms, changes in blood cell counts or other signs that may indicate a need for treatment.

Targeted Therapy: Medicines that target abnormal cellular signalling pathways may help to reduce symptoms and control certain effects of myelofibrosis. JAK inhibitors including ruxolitinib for appropriate patients, may reduce spleen enlargement and improve symptoms. The choice of medicine depends on the patient's condition, treatment history, eligibility and potential adverse effects.

Blood Transfusions and Anaemia Management: People with severe anaemia may require red blood cell transfusions. Depending on the severity and cause of anaemia, doctors may prescribe erythropoietin or darbepoetin to stimulate red blood cell production. In selected cases, medicines such as danazol or prednisone may also help manage anaemia.

Other Medicines: Depending on blood counts and symptoms, doctors may use other drug treatments to manage complications or control abnormal blood cell production. Treatment selection requires consideration of potential adverse effects and the patient's overall health.

Radiation Therapy or Splenectomy: If an enlarged spleen causes substantial discomfort or other complications, selected patients may receive radiation therapy or undergo splenectomy, which is the surgical removal of the spleen. These approaches are not suitable for everyone and carry specific risks.

Allogeneic Stem Cell Transplant: A stem cell transplant using cells from a donor is the principal treatment with the potential to cure myelofibrosis. However, the transplant can cause serious and potentially life-threatening complications. Doctors consider an allogeneic stem cell transplant only when the potential benefits outweigh the risks, taking into account the patient's age, disease risk, overall health and donor availability.

Treatment may change over time as the disease progresses or a person's response to medicines changes. Follow-up appointments and blood tests help the medical team monitor effectiveness, manage adverse effects and reconsider treatment when required. There is no treatment which may be appropriate for every patient. Decisions should be made with a haematologist who can explain the likely benefits, risks and alternatives for the individual's circumstances.

A diagnosis of myelofibrosis may involve regular medical appointments, medicines, blood transfusions and other treatment expenses. Critical illness insurance may pay a benefit if the diagnosed condition meets the policy's definition and all other claim requirements are fulfilled. However, the diagnosis of a disease does not automatically establish eligibility for a claim.

The distinction is particularly important when a policy defines a condition according to its severity, permanence or treatment requirements. The applicable policy wording should therefore be checked before assuming that a myelofibrosis diagnosis qualifies for a benefit.

Critical illness cover should be assessed against medical needs, financial responsibilities and the precise terms of the policy. A policy may cover many critical illnesses but each condition has specific medical criteria that must be met for a claim to qualify. It is important to check the following details before choosing critical illness cover.

• List of Covered Conditions: Confirm whether myelofibrosis is explicitly listed and whether it falls under the selected variant. Do not assume that a condition is covered simply because related blood disorders or cancers appear in the policy.
• Medical Definition: The policyholder should read the complete definition of each relevant illness. Check whether it requires a specific level of severity, permanent impairment, a diagnostic procedure, a particular treatment or ongoing transfusions.
• Waiting and Survival Periods: Check when coverage begins and whether a waiting period applies after policy issuance or revival. Also confirm how long the insured person must survive after diagnosis for the claim to qualify.
• Exclusions and Limitations: Read the exclusions, claim restrictions and other terms that may affect eligibility. Obtain clarification from the insurer if any wording is unclear.
• Benefit Amount and Payout Structure: Check the sum assured for major critical illness, whether a previous minor illness claim reduces the available benefit, and whether a claim affects the remaining rider cover.
• Medical Disclosure and Underwriting: Provide accurate information about previous diagnoses, investigations, symptoms and treatment when applying for cover. An existing health condition may affect underwriting or the policy terms offered by the insurer.

Reading the policy wording before purchasing the health insurance may help you to set clear expectations. Compare policy definitions and conditions rather than choosing a policy solely on the basis of its premium or the number of illnesses covered.

Myelofibrosis is a bone marrow disorder that can interfere with healthy blood cell production and lead to anaemia, an enlarged spleen, fatigue and other complications. Its course varies considerably, and diagnosis may involve blood tests, bone marrow examination and molecular testing. Treatment can range from regular monitoring and symptom management to targeted medicines or a stem cell transplant for suitable patients.

Critical illness insurance may help you with financial support when your medical condition matches the policy definition. A diagnosis of myelofibrosis alone may not qualify for a critical illness benefit. The policy may also require the condition to be permanent and meet specific treatment criteria. Reviewing the covered variant, medical definition, waiting period, survival period and claim requirements is therefore essential before relying on a potential benefit.

Disclaimer: The information provided in this article is for general informational and educational purposes only and should not be construed as medical advice, diagnosis, treatment recommendation, or professional healthcare guidance. Treatment costs mentioned are indicative and may vary based on factors such as the patient's medical condition, hospital, city, surgeon's expertise, room category, and other treatment-related requirements. Readers are advised to consult qualified healthcare professionals and obtain cost estimates directly from healthcare providers before making any medical or financial decisions. Axis Max Life Insurance does not provide medical services, endorse any specific healthcare provider.